PMID- 27780736
OWN - NLM
STAT- MEDLINE
DCOM- 20171219
LR  - 20180611
IS  - 1873-5169 (Electronic)
IS  - 0196-9781 (Linking)
VI  - 86
DP  - 2016 Dec
TI  - Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus 
      treated with metformin and miglitol can maintain higher concentrations of 
      biologically active GLP-1/total GIP and a lower concentration of leptin.
PG  - 118-125
LID - S0196-9781(16)30214-5 [pii]
LID - 10.1016/j.peptides.2016.10.011 [doi]
AB  - Metformin, alpha-glucosidase inhibitors (alpha-GIs), and dipeptidyl peptidase 4 
      inhibitors (DPP-4Is) reduce hyperglycemia without excessive insulin secretion, 
      and enhance postprandial plasma concentration of glucagon-like peptide-1 (GLP-1) 
      in type-2 diabetes mellitus (T2DM) patients. We assessed add-on therapeutic 
      effects of DPP-4I anagliptin in Japanese T2DM patients treated with metformin, an 
      alpha-GI miglitol, or both drugs on postprandial responses of GLP-1 and 
      glucose-dependent insulinotropic polypeptide (GIP), and on plasma concentration 
      of the appetite-suppressing hormone leptin. Forty-two Japanese T2DM patients with 
      inadequately controlled disease (HbA1c: 6.5%-8.0%) treated with metformin (n=14), 
      miglitol (n=14) or a combination of the two drugs (n=14) received additional 
      treatment with anagliptin (100mg, p.o., b.i.d.) for 52 weeks. We assessed 
      glycemic control, postprandial responses of GLP-1 and glucose-dependent 
      insulinotropic polypeptide (GIP), and on plasma concentration of leptin in those 
      patients. Add-on therapy with anagliptin for 52 weeks improved glycemic control 
      and increased the area under the curve of biologically active GLP-1 concentration 
      without altering obesity indicators. Total GIP concentration at 52 weeks was 
      reduced by add-on therapy in groups treated with miglitol compared with those 
      treated with metformin. Add-on therapy reduced leptin concentrations. Add-on 
      therapy with anagliptin in Japanese T2DM patients treated with metformin and 
      miglitol for 52 weeks improved glycemic control and enhanced postprandial 
      concentrations of active GLP-1/total GIP, and reduce the leptin concentration.
CI  - Copyright A(c) 2016 Elsevier Inc. All rights reserved.
FAU - Osonoi, Takeshi
AU  - Osonoi T
AD  - Naka Kinen Clinic, Ibaraki 311-0113, Japan. Electronic address: 
      t-osonoi@kensei-kai.com.
FAU - Saito, Miyoko
AU  - Saito M
AD  - Naka Kinen Clinic, Ibaraki 311-0113, Japan.
FAU - Hariya, Natsuyo
AU  - Hariya N
AD  - Department of Epigenetic Medicine, Faculty of Medicine, University of Yamanashi, 
      Yamanashi 409-3898, Japan.
FAU - Goto, Moritaka
AU  - Goto M
AD  - Pharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd., Mie 
      511-0406, Japan.
FAU - Mochizuki, Kazuki
AU  - Mochizuki K
AD  - Laboratory of Food and Nutritional Sciences, Department of Local Produce and Food 
      Sciences, Faculty of Life and Environmental Sciences, University of Yamanashi, 
      Yamanashi 400-8510, Japan. Electronic address: mochizukik@yamanashi.ac.jp.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161022
PL  - United States
TA  - Peptides
JT  - Peptides
JID - 8008690
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Leptin)
RN  - 0 (Pyrimidines)
RN  - 0V5436JAQW (miglitol)
RN  - 19130-96-2 (1-Deoxynojirimycin)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9100L32L2N (Metformin)
RN  - K726J96838 (anagliptin)
SB  - IM
MH  - 1-Deoxynojirimycin/*analogs & derivatives/pharmacology/therapeutic use
MH  - Aged
MH  - Blood Glucose
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gastric Inhibitory Polypeptide/blood
MH  - Glucagon-Like Peptide 1/blood
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Leptin/blood
MH  - Male
MH  - Metformin/pharmacology/*therapeutic use
MH  - Middle Aged
MH  - Pyrimidines/pharmacology/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - &alpha
OT  - DPP-4I
OT  - GLP-1
OT  - Metformin
OT  - Type-2 diabetes mellitus
EDAT- 2016/10/27 06:00
MHDA- 2017/12/20 06:00
CRDT- 2016/10/27 06:00
PHST- 2016/07/08 00:00 [received]
PHST- 2016/10/21 00:00 [revised]
PHST- 2016/10/21 00:00 [accepted]
PHST- 2016/10/27 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
PHST- 2016/10/27 06:00 [entrez]
AID - S0196-9781(16)30214-5 [pii]
AID - 10.1016/j.peptides.2016.10.011 [doi]
PST - ppublish
SO  - Peptides. 2016 Dec;86:118-125. doi: 10.1016/j.peptides.2016.10.011. Epub 2016 Oct 
      22.